In the article “Biotech in the Balance,” Dr. Jeremy Levin, Chair of Ovid Therapeutics, discusses the biotech industry’s current challenges and future potential amidst growing public distrust. He stresses the industry’s need to reconnect with its “covenant with the patient,” emphasizing the complexities of drug pricing and the importance of transparency. Furthermore, Dr. Levin warns that America’s position as a leader in biotechnology is at risk, particularly with China prioritizing biotech development. The conversation highlights the urgency of addressing these issues to ensure innovations in healthcare occur domestically rather than abroad.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.marketscale.com/industries/healthcare/biotech-in-the-balance-dr-jeremy-levin-author-and-chair-of-ovid-therapeutics
